BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED Financials Bharat Immunologicals & Biologicals Corporation Limited
Equities
BIBCL6
INE994B01014
Pharmaceuticals
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 31.39 INR | -2.39% |
|
+5.37% | -11.20% |
Valuation
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 850.6 | 332.1 | 251.3 | 1,965 | 1,213 | 958.2 |
| Enterprise Value (EV) 1 | 704.4 | 629.2 | 271.8 | 2,225 | 1,946 | 1,648 |
| P/E ratio | -19.9 x | -5.73 x | -2.46 x | -10.8 x | -13.8 x | -5.76 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 2.44 x | 0.4 x | 0.38 x | 2.3 x | 1.55 x | 2.15 x |
| EV / Revenue | 2.02 x | 0.75 x | 0.41 x | 2.61 x | 2.48 x | 3.69 x |
| EV / EBITDA | -8.78 x | -6.75 x | -2.65 x | -10.7 x | -39.3 x | -10.4 x |
| EV / FCF | -4.18 x | -1.77 x | 0.74 x | - | -4.08 x | 13.2 x |
| FCF Yield | -24% | -56.5% | 135% | - | -24.5% | 7.6% |
| Price to Book | 2.27 x | 1.08 x | 1.23 x | 5.77 x | 1.15 x | 1.09 x |
| Nbr of stocks (in thousands) | 43,180 | 43,180 | 43,180 | 43,180 | 43,180 | 43,180 |
| Reference price 2 | 19.70 | 7.690 | 5.820 | 45.50 | 28.10 | 22.19 |
| Announcement Date | 8/29/18 | 9/29/19 | 12/29/20 | 11/8/21 | 9/23/22 | 12/13/23 |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 348 | 836.5 | 668.4 | 853.3 | 783.9 | 446.1 |
| EBITDA 1 | -80.22 | -93.18 | -102.5 | -208.5 | -49.5 | -158.5 |
| EBIT 1 | -84.36 | -95.94 | -104.9 | -210.9 | -51.63 | -160.5 |
| Operating Margin | -24.24% | -11.47% | -15.69% | -24.71% | -6.59% | -35.98% |
| Earnings before Tax (EBT) 1 | -79.59 | -73.74 | -142 | -242.1 | -96.87 | -222.7 |
| Net income 1 | -42.62 | -57.93 | -102.1 | -181.1 | -87.54 | -166.4 |
| Net margin | -12.25% | -6.93% | -15.28% | -21.23% | -11.17% | -37.3% |
| EPS 2 | -0.9900 | -1.342 | -2.365 | -4.195 | -2.030 | -3.853 |
| Free Cash Flow 1 | -168.7 | -355.8 | 367.5 | - | -476.8 | 125.2 |
| FCF margin | -48.48% | -42.54% | 54.98% | - | -60.83% | 28.08% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/29/18 | 9/29/19 | 12/29/20 | 11/8/21 | 9/23/22 | 12/13/23 |
1INR in Million2INR
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 297 | 20.5 | 261 | 732 | 689 |
| Net Cash position 1 | 146 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -3.189 x | -0.2003 x | -1.25 x | -14.8 x | -4.349 x |
| Free Cash Flow 1 | -169 | -356 | 367 | - | -477 | 125 |
| ROE (net income / shareholders' equity) | -10.8% | -17% | -39.9% | -66.5% | -12.6% | -17.2% |
| ROA (Net income/ Total Assets) | -9.39% | -6.72% | -5.21% | -11.4% | -2.04% | -5% |
| Assets 1 | 453.9 | 861.6 | 1,961 | 1,586 | 4,296 | 3,329 |
| Book Value Per Share 2 | 8.680 | 7.100 | 4.740 | 7.880 | 24.40 | 20.40 |
| Cash Flow per Share 2 | 0.2800 | 0.0900 | 0.2300 | 0.2800 | 1.080 | 0.3000 |
| Capex 1 | 0.02 | 0.25 | 0.01 | - | - | - |
| Capex / Sales | 0.01% | 0.03% | 0% | - | - | - |
| Announcement Date | 8/29/18 | 9/29/19 | 12/29/20 | 11/8/21 | 9/23/22 | 12/13/23 |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -11.20% | 16.65M | |
| -4.06% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- BIBCL6 Stock
- Financials Bharat Immunologicals & Biologicals Corporation Limited
